MKK4

EQS-News: HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

Retrieved on: 
Wednesday, April 10, 2024
Liver, Liver failure, DOI, Cell death, Regeneration, Clinical professor, Colorectal cancer, Transplant, Hepatectomy, Risk, Patient, MKK4, Mayo Clinic, Manuscript, Liver transplantation, Teaching hospital, Human, MAP, Liver regeneration, Hepatocyte, PHLF, Regenerative medicine, Safety, Hepatology, Liver disease, Dietary supplement

HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).

Key Points: 
  • HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).
  • "The positive results in terms of safety and tolerability confirm our intention to soon offer a drug that has the potential to revolutionize the treatment of severe liver diseases.
  • The data pave the way for further Phase II studies evaluating the efficacy of HRX-215 in humans," emphasizes Dr. Wolfgang Albrecht, COO of HepaRegeniX.
  • Further, HRX-215 was also able to protect hepatocytes from cell death in a model for acute liver injury.

HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

Retrieved on: 
Thursday, March 14, 2024
Liver, Liver failure, DOI, Cell death, Regeneration, Clinical professor, Colorectal cancer, Transplant, Gesellschaft mit beschränkter Haftung, Hepatectomy, Risk, Patient, MKK4, Mayo Clinic, Manuscript, Liver transplantation, Teaching hospital, Human, MAP, Liver regeneration, Hepatocyte, PHLF, Regenerative medicine, Safety, Hepatology, Liver disease, Dietary supplement

HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).

Key Points: 
  • HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).
  • “The positive results in terms of safety and tolerability confirm our intention to soon offer a drug that has the potential to revolutionize the treatment of severe liver diseases.
  • The data pave the way for further Phase II studies evaluating the efficacy of HRX-215 in humans,” emphasizes Dr. Wolfgang Albrecht, COO of HepaRegeniX.
  • Further, HRX-215 was also able to protect hepatocytes from cell death in a model for acute liver injury.

EQS-News: HepaRegeniX appoints Dr. Andreas Busch as Senior Advisor

Retrieved on: 
Sunday, November 27, 2022
Doctor of Philosophy, German Cancer Aid, MKK4, 2021 Essex County Council election, University, Therapy, Bayer, Sanofi, Patient, Senior advisor, Liver regeneration, Max Planck Institute for Molecular Genetics, Max, German Cancer Research Center, Transplant, Innovation, Max Planck Society, Pharmacy, Shire, Research, Publication, Hoechst, Survival, Takeda, Drug discovery, Pharmaceutical industry, Pharmacology

Tbingen (Germany), November 23, 2022 HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapy approaches for the treatment of acute and chronic liver diseases, announced today the appointment of Dr. Andreas Busch as Senior Advisor.

Key Points: 
  • Tbingen (Germany), November 23, 2022 HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapy approaches for the treatment of acute and chronic liver diseases, announced today the appointment of Dr. Andreas Busch as Senior Advisor.
  • We are thrilled to welcome Andreas Busch to our team.
  • Dr. Andreas Busch added: There is an enormous lack of organs for transplantation including of livers despite their unique inherent regenerative capabilities.
  • Dr. Andreas Busch has an extensive track record in facilitating innovation both in the pharmaceutical industry as well as in academic research.

DGAP-News: HepaRegeniX reports positive topline results of its Phase 1 Clinical Trial of HRX-0215, a First-In-Class MKK4 inhibitor

Retrieved on: 
Thursday, May 12, 2022
ECG, COO, Vital signs, Liver regeneration, Liver, Pharmacokinetics, MAP, Volunteering, MKK4, Clinical trial, Safety, Regeneration, Hepatocyte, Male, Pharmaceutical industry, Dietary supplement

HepaRegeniX reports positive topline results of its Phase 1 Clinical Trial of HRX-0215, a First-In-Class MKK4 inhibitor

Key Points: 
  • HepaRegeniX reports positive topline results of its Phase 1 Clinical Trial of HRX-0215, a First-In-Class MKK4 inhibitor
    The issuer is solely responsible for the content of this announcement.
  • HepaRegeniX reports positive topline results of its Phase 1 Clinical Trial of HRX-0215,
    Tbingen (Germany), May 12, 2022 HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapy approaches for the treatment of acute and chronic liver diseases, announced today the successful conclusion and top-line results of its Phase 1 clinical trial for its lead drug candidate HRX-0215.
  • HRX-0215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4), a key regulator of liver regeneration.
  • During the Phase 1 trial, HRX-0215 was well tolerated at all doses with no drug-related adverse events being observed.

DGAP-News: HepaRegeniX to present key results on MKK4 inhibitors and their therapeutic efficacy at upcoming scientific conferences

Retrieved on: 
Thursday, November 4, 2021
Safety, AASLD, Research, 2021 Essex County Council election, TLM, Cirrhosis, Association, Mayo Clinic, Hepatectomy, Liver regeneration, Patient, Gesellschaft mit beschränkter Haftung, Liver disease, Volume, American Association for the Study of Liver Diseases, CEO, Clinical professor, MKK4, Oncology, Liver, American Association, Hope, Pulmonology, Doctor of Philosophy, Department, Pharmaceutical industry, Dietary supplement

This presentation will feature key results, which were generated by Prof Lars Zender and his research group in close collaboration with HepaRegeniX.

Key Points: 
  • This presentation will feature key results, which were generated by Prof Lars Zender and his research group in close collaboration with HepaRegeniX.
  • "We are excited to present new evidence for safety and efficacy of MKK4 inhibition at two leading conferences within a few days and look forward to inspiring scientific discussions around MKK4 inhibition," said Dr. Michael Lutz, CEO of HepaRegeniX.
  • "The excellent results of our studies with MKK4 inhibitors in preclinical models of acute and chronic liver diseases confirm our therapeutic rationale.
  • Details of the upcoming events:
    The Liver Meeting (TLM) of the American Association for the Study of Liver Disease (AASLD), Nov 12-15, 2021
    For further information please contact:

DGAP-News: HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute to explore the potential of its 2nd MKK4 inhibitor HRX-0233 for use in cancer combination ther

Retrieved on: 
Wednesday, October 20, 2021
Netherlands Cancer Institute, Biology, Dutch Cancer Society, MAP2K4, MAP, All European Academies, Colorectal cancer, Diagnosis, KRAS, Translational research, News, MEK, Valorisation, MKK4, DGAP, Cancer research, Research, Cancer Science, Liver regeneration, Quality of life, Justicia oncodes, Hepatocyte, Patient, Economy, Novo Holdings A/S, Cancer, Pharmaceutical industry, HepaRegeniX GmbH -, the Oncode Institute, Utrecht, HEPAREGENIX GMBH -, THE ONCODE INSTITUTE, UTRECHT

MKK4 is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers.

Key Points: 
  • MKK4 is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers.
  • This new and unique therapeutic concept was discovered by Prof. Lars Zender and his research group at the University Hospital Tubingen, Germany.
  • Investors in HepaRegeniX include the Boehringer Ingelheim Venture Fund (BIVF), Novo Holdings A/S, Coparion, High-Tech Gruenderfonds and Ascenion GmbH.
  • About the Netherlands Cancer Institute, Amsterdam - www.nki.nl
    The Netherlands Cancer Institute , founded in 1913, is among the world's best comprehensive cancer centers, combining world-class fundamental, translational, and clinical research with dedicated patient care.

DGAP-News: HepaRegeniX initiates first-in-man Phase 1 trial for its lead MKK4 inhibitor HRX 0215

Retrieved on: 
Tuesday, August 10, 2021
Data, Hepatocellular carcinoma, CEO, Quality of life, Male, Hepatocyte, Prognosis, Pharmacokinetics, Cancer, MKK4, Medicine, MAP, Liver, Patient, List of hepato-biliary diseases, Liver regeneration, Safety, Gesellschaft mit beschränkter Haftung, Volunteering, Chronic liver disease, Pharmaceutical industry, Dietary supplement, HRX-0215, HepaRegeniX GmbH -, HRX-0215, HEPAREGENIX GMBH -

Tubingen (Germany), August 10, 2021 - HepaRegeniX GmbH, a clinical stage company developing novel therapies for the treatment of acute and chronic liver diseases, announced today the first dosing of its lead drug candidate HRX-0215 in a Phase 1 clinical trial.

Key Points: 
  • Tubingen (Germany), August 10, 2021 - HepaRegeniX GmbH, a clinical stage company developing novel therapies for the treatment of acute and chronic liver diseases, announced today the first dosing of its lead drug candidate HRX-0215 in a Phase 1 clinical trial.
  • HRX-0215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4), a key regulator of liver regeneration.
  • Suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers.
  • The trial will assess the safety, tolerability, and pharmacokinetics of HRX-0215 and is designed as a single and multiple dose escalation study (SAD/MAD).